Dr. Allan Jaffe
Dr. Jaffe was raised in the suburbs of Washington D.C. in Silver Spring and Bethesda Maryland. He went to college at the University of Rochester and then at the University of Maryland where he also went to Medical School. He did his house office training in Internal Medicine and his fellowship in Cardiology at Washington University School of Medicine and Barnes Hospital in St. Louis Missouri. He stayed on the faculty after his training as a clinical cardiologist and eventually became responsible for the CCU and the CCU biochemistry laboratory which is where all the biomarker assays used in the CCU were run. It is there that he became involved first with CKMB assays and subsequently with the development and validation of the cardiac troponin assays. With time, Dr. Jaffe became a full Professor at Washington University and had a robust NIH funded career there helping to develop biochemical markers of thrombosis, fibrinolysis, inflammation and myocardial injury. In 1995, he moved to be Chief of Cardiology and Associate Chief of Medicine for Academic Affairs at the State University of New York at Syracuse and after 4 years there, he was recruited to the Mayo Clinic in both Cardiology and Laboratory Medicine. He remains a practicing cardiologist and is the Medical Director of CVLM. Dr. Jaffe is widely published and is internationally and nationally known for his work on biomarkers. Dr. Jaffe is very active in professional societies, where he serves on the SIRB NIH study section, is the Co-Chairman of the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study, and is the leader of the Biochemistry panel on the Global Task Force on the Redefinition of AMI. He is also involved with the ACC, AHA, AACC, and NACB, on numerous editorial boards and guidelines committees.